Zika: the Emerging Epidemic
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Exploring Mental Health & COVID-19: How a Pandemic Could Become
Eastern Kentucky University Encompass Honors Theses Student Scholarship Spring 5-2021 Exploring Mental Health & COVID-19: How a Pandemic Could Become America's Next Mental Health Crisis Ashley D. Shofner Eastern Kentucky University, [email protected] Follow this and additional works at: https://encompass.eku.edu/honors_theses Recommended Citation Shofner, Ashley D., "Exploring Mental Health & COVID-19: How a Pandemic Could Become America's Next Mental Health Crisis" (2021). Honors Theses. 834. https://encompass.eku.edu/honors_theses/834 This Open Access Thesis is brought to you for free and open access by the Student Scholarship at Encompass. It has been accepted for inclusion in Honors Theses by an authorized administrator of Encompass. For more information, please contact [email protected]. EASTERN KENTUCKY UNIVERSITY Exploring Mental Health and COVID-19: How a Pandemic Could Become America’s Next Mental Health Crisis Honors Thesis Submitted in Partial Fulfillment of the Requirements of HON 420 Spring 2021 By Ashley D. Shofner Mentor Dr. Molly A. McKinney Associate Professor, Department of Health Promotion and Administration 3 An Abstract Of Exploring Mental Health and COVID-19: How a Pandemic Could Become America’s Next Mental Health Crisis By Ashley D. Shofner Mentor Dr. Molly A. McKinney Associate Professor, Department of Health Promotion and Administration Abstract Description: A pandemic can be described as an epidemic disease that has spread over a large geographical area and has become prevalent in numerous sectors of the globe. In 2020, just over 100 years since our last major pandemic, the 1918 Influenza outbreak, the global community is facing yet another threat: COVID-19. -
Ebola Virus Disease
Outbreaks Chronology: Ebola Virus Disease Known Cases and Outbreaks of Ebola Virus Disease, in Reverse Chronological Order: Reported number (%) of Reported deaths Ebola number of among Year(s) Country subtype human cases cases Situation August- Democratic Ebola virus 66 49 (74%) Outbreak occurred in November 2014 Republic of multiple villages in the Congo the Democratic Republic of the Congo. The outbreak was unrelated to the outbreak of Ebola in West Africa. March 2014- Multiple Ebola virus 28652 11325 Outbreak across Present countries multiple countries in West Africa. Number of patients is constantly evolving due to the ongoing investigation. 32 November 2012- Uganda Sudan virus 6* 3* (50%) Outbreak occurred in January 2013 the Luwero District. CDC assisted the Ministry of Health in the epidemiologic and diagnostic aspects of the outbreak. Testing of samples by CDC's Viral Special Pathogens Branch occurred at UVRI in Entebbe. 31 June-November Democratic Bundibugyo 36* 13* (36.1%) Outbreak occurred in 2012 Republic of virus DRC’s Province the Congo Orientale. Laboratory support was provided through CDC and the Public Health Agency of Canada (PHAC)’s field laboratory in Isiro, as well as through the CDC/UVRI lab in Uganda. The outbreak in DRC had no epidemiologic link to the near contemporaneous Ebola outbreak in the Kibaale district of Uganda. 31 June-October Uganda Sudan virus 11* 4* (36.4%) Outbreak occurred in 2012 the Kibaale District of Uganda. Laboratory tests of blood samples were conducted by the UVRI and the CDC. 31 May 2011 Uganda Sudan virus 1 1 (100%) The Uganda Ministry of Health informed the public a patient with suspected Ebola Hemorrhagic fever died on May 6, 2011 in the Luwero district, Uganda. -
CEPI and COVID-19 VACCINES
CEPI and COVID-19 VACCINES June 9, 2020 Nicole Lurie, MD, MSPH Strategic Advisor to the CEO and Incident Manager, COVID response team CEPI A world in which epidemics are no longer a threat to humanity CEPI accelerates development of vaccines against emerging infectious diseases and enables equitable access to these vaccines for affected populations during outbreaks 2 Image left slide (right-click to replace image) CEPI Strategic Objectives Preparedness Response Sustainability Advance access to safe and Accelerate the research, Create durable and equitable effective vaccines against development and use of solutions for outbreak emerging infectious diseases vaccines during outbreaks response capacity 3 3 Column slide Small images or graphics can be used to highlight key items. These should always be circular CEPI has multiple investments against its priority pathogens MERS Lassa Nipah Chikungunya Rift Valley fever Disease X 5 vaccine 6 vaccine 4 vaccine 2 vaccine 2 vaccine 3 platform candidates candidates candidates candidates candidates technologies 4 COVID-19 portfolio goals Speed Scale Access Developing Covid-19 vaccines at Scaling up and scaling out vaccine Working with global partners to pandemic speed manufacturing capacity ensure fair allocation of COVID-19 vaccines 5 CEPI vaccine development so far…. 23th May 31st Dec 2019 11th March 12th April 14th Feb First meeting of the ACT WHO notified of pneumonia-like case Wellcome Trust launch First cases reported in WHO declares Accelerator cluster in Wuhan, China COVID-Zero resource Africa -
Replication of Marburg Virus in Human Endothelial Cells a Possible Mechanism for the Development of Viral Hemorrhagic Disease
Replication of Marburg Virus in Human Endothelial Cells A Possible Mechanism for the Development of Viral Hemorrhagic Disease Hans-Joachim Schnittler,$ Friederike Mahner, * Detlev Drenckhahn, * Hans-Dieter Klenk, * and Heinz Feldmann * *Institut fir Virologie, Philipps-Universitdt Marburg, 3550 Marburg, Germany; tInstitutftirAnatomie, Universitdt Wiirzburg, 8700 Wiirzburg, Germany Abstract Rhabdoviridae, within the new proposed order Mononegavi- Marburg and Ebola virus, members of the family Filoviridae, rales (10). Virions are composed of a helical nucleocapsid cause a severe hemorrhagic disease in humans and primates. surrounded by a lipid envelope. The genome is nonsegmented, The disease is characterized as a pantropic virus infection often of negative sense, and 19 kb in length (3, 11, 12). Virion parti- resulting in a fulminating shock associated with hemorrhage, cles contain at least seven structural proteins (8, 13-16). and death. All known histological and pathophysiological pa- Filovirus infections have several pathological features in rameters of the disease are not sufficient to explain the devas- common with other severe viral hemorrhagic fevers such as tating symptoms. Previous studies suggested a nonspecific de- Lassa fever, hemorrhagic fever with renal syndrome, and struction of the endothelium as a possible mechanism. Con- Dengue hemorrhagic fever (5). Among these viruses, filovi- cerning the important regulatory functions of the endothelium ruses cause the highest case-fatality rates ( - 35% for MBG [61 (blood pressure, antithrombogenicity, homeostasis), we exam- and up to 90% for EBO, subtype Zaire [17]) and the most ined Marburg virus replication in primary cultures of human severe hemorrhagic manifestations. The pathophysiologic endothelial cells and organ cultures of human umbilical cord events that make filovirus infections of humans so devastating veins. -
Comparison and Evaluation of Real-Time Taqman PCR for Detection and Quantification of Ebolavirus
viruses Article Comparison and Evaluation of Real-Time Taqman PCR for Detection and Quantification of Ebolavirus Yi Huang 1,* , Shuqi Xiao 2 and Zhiming Yuan 1,* 1 National Biosafety Laboratory, Chinese Academy of Sciences, Wuhan 430020, China 2 Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430020, China; [email protected] * Correspondence: [email protected] (Y.H.); [email protected] (Z.Y.) Abstract: Given that ebolavirus causes severe and frequently lethal disease, its rapid and accurate detection using available and validated methods is essential for controlling infection. Real-time reverse-transcription PCR (RT-PCR) has proven to be an invaluable tool for ebolaviruses diagnostics. Many assays with different targets have been developed, but they have not been externally compared or validated, and limits of detection are not uniformly reported. Here we compared and evaluated the sensitivity, reproducibility and specificity of 23 in-house assays under the same conditions. Our results showed that these assays were highly gene- and species- specific when evaluated using in vitro RNA transcripts and viral RNA, and the potential limits of detection were uniformly reported 2 6 ranging from 10 to 10 in vitro synthesized RNA transcripts copies perµL and 1–100 TCID50/mL. The comparison of these assays indicated that those targeting the more conservative NP gene could be the better option for EVD case definition and quantitative measurement because of its higher sensitivity for the same species. Our analysis could contribute to the standardization of ebolavirus detection and quantification assays, which can offer a better understanding of the meaning of results across laboratories and time points, as well as make them easy to implement, especially under outbreak conditions. -
COVID-19 (Novel Coronavirus): What We Know, What We Don’T Know, and How We Can Plan Within Our Communities
COVID-19 (novel coronavirus): What we know, what we don’t know, and how we can plan within our communities March 5, 2020 Andrew Lover, MS MPH PhD Dept. of Biostatistics and Epidemiology [email protected] School of Public Health and Health Sciences Updated Mar 7; v1.1. Overview 1. Some background 2. The virus and epidemiology 3. Response measures and community preparedness 4. Q & A School of Public Health and Health Sciences 2 Disclaimers All opinions in this talk are my personal views, and do not represent those of the Department of Biostatistics and Epidemiology; the School of Public Health and Health Sciences; or UMass-Amherst. Guidance is being rapidly updated; always consult your local, state and federal authorities for the most up-to-date information. (mass.gov and cdc.gov) General note: most/many current studies are preprints and are not yet peer reviewed; and data change hourly/daily. School of Public Health and Health Sciences 3 Terminology § Coronaviruses are a small class of human pathogens; four of which cause ‘normal’ respiratory infections. § Two others may cause severe infections: SARS-CoV, and MERS-CoV. MERS-CoV § Original name (Jan 2020): Wuhan flu or novel coronavirus-2019 § Current standard (allows for expansion) § Illness: COVID-19 (“coronavirus disease”) § Virus: SARS-CoV-2 § This structure parallels HIV/AIDS School of Public Health and Health Sciences 4 Population-level metrics § Endemic: The constant presence of a disease or infectious agent within a given geographic area or population group § Epidemic: The occurrence in a community or region of cases of an illness clearly in “excess of normal expectancy” (preferred) § Outbreak: An epidemic limited to localized increase in the incidence of a disease (avoid) § Pandemic: An epidemic occurring over a very wide area, crossing international boundaries and usually affecting a large number of people (national or global), but no specific criteria School of Public Health and Health Sciences 5 The first signal…. -
Biomarker Correlates of Survival in Pediatric Patients with Ebola Virus Disease
Emerging Infectious Diseases. Volume 20, Number 10—October 2014 CDC EID journal Ahead of Print / In Press Research Biomarker Correlates of Survival in Pediatric Patients with Ebola Virus Disease Anita K. McElroy , Bobbie R. Erickson, Timothy D. Flietstra, Pierre E. Rollin, Stuart T. Nichol, Jonathan S. Towner, and Christina F. Spiropoulou Author affiliations: Emory University, Atlanta, Georgia, USA (A.K. McElroy); Centers for Disease Control and Prevention, Atlanta (A.K. McElroy, B.R. Erickson, T.D. Flietstra, P.E. Rollin, S.T. Nichol, J.S. Towner, C.F. Spiropoulou) Suggested citation for this article Abstract Outbreaks of Ebola virus disease (EVD) occur sporadically in Africa and are associated with high case-fatality rates. Historically, children have been less affected than adults. The 2000–2001 Sudan virus–associated EVD outbreak in the Gulu district of Uganda resulted in 55 pediatric and 161 adult laboratory-confirmed cases. We used a series of multiplex assays to measure the concentrations of 55 serum analytes in specimens from patients from that outbreak to identify biomarkers specific to pediatric disease. Pediatric patients who survived had higher levels of the chemokine regulated on activation, normal T-cell expressed and secreted marker and lower levels of plasminogen activator inhibitor 1, soluble intracellular adhesion molecule, and soluble vascular cell adhesion molecule than did pediatric patients who died. Adult patients had similar levels of these analytes regardless of outcome. Our findings suggest that children with EVD may benefit from different treatment regimens than those for adults. Outbreaks of Ebola virus disease (EVD) occur sporadically in sub-Saharan Africa and are associated with exceptionally high case-fatality rates (CFRs). -
To Ebola Reston
WHO/HSE/EPR/2009.2 WHO experts consultation on Ebola Reston pathogenicity in humans Geneva, Switzerland 1 April 2009 EPIDEMIC AND PANDEMIC ALERT AND RESPONSE WHO experts consultation on Ebola Reston pathogenicity in humans Geneva, Switzerland 1 April 2009 © World Health Organization 2009 All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distin- guished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization. -
An Overview of COVID-19 Vaccine Efficacy Trials
An Overview of COVID-19 Vaccine Efficacy Trials NISS-Merck Meet Up January 13, 2021 \ Natalie Dean Department of Biostatistics PHHP/COM Emerging Pathogens Institute University of Florida [email protected] VACCINE BASICS COVID- 19 VACCINES WHO R&D Blueprint Prioritized pathogens Crimean Congo Hemorrhagic Fever (CCHF) Ebola and Marburg virus disease Lassa fever MERS-CoV and SARS Nipah and henipaviral diseases Rift Valley Fever (RVF) Zika Disease X COVID- 19 VACCINES Expectations for COVID-19 vaccines “The principal goal of a vaccine efficacy trial is to obtain efficacy and effectiveness data that can support broader use of a vaccine under a defined regulatory framework.” Intended use for COVID-19: billions vaccinated Dean et al. 2019 https://stm.sciencemag.org/content/11/499/eaat0360.abstract COVID- 19 VACCINES Regulatory pathway for vaccines Preclinical data REGULATORY Phase 1 trials Evidence of safety APPROVAL and anti-disease Phase 2 trials activity in animals Smallest trials Phase 3 trials Requires a First-in-human Larger trials validated animal Focus on safety model More safety data Largest trials Establish dosing More immune Field trials Some immune response data response data Disease-related Explore sub- primary outcome groups (e.g. prevent COVID-19) More safety data COVID- 19 VACCINES Accelerating this pathway during a pandemic Accelerated review process Emergency Use Authorization instead of full licensure Preclinical data REGULATORY Phase 1 trials Evidence of safety APPROVAL and anti-disease Phase 2 trials activity in animals Smallest trials Phase 3 trials Requires a First-in-human Larger trials validated animal Focus on safety model More safety data Largest trials Establish dosing More immune Field trials Some immune response data Disease-related response data Explore sub- Start scaling up manufacturing primary outcome before receiving regulatory groups (e.g. -
Understanding Ebola
Understanding Ebola With the arrival of Ebola in the United States, it's very easy to develop fears that the outbreak that has occurred in Africa will suddenly take shape in your state and local community. It's important to remember that unless you come in direct contact with someone who is infected with the disease, you and your family will remain safe. State and government agencies have been making preparations to address isolated cases of infection and stop the spread of the disease as soon as it has been positively identified. Every day, the Centers of Disease Control and Prevention (CDC) is monitoring developments, testing for suspected cases and safeguarding our lives with updates on events and the distribution of educational resources. Learning more about Ebola and understanding how it's contracted and spread will help you put aside irrational concerns and control any fears you might have about Ebola severely impacting your life. Use the resources below to help keep yourself calm and focused during this unfortunate time. Ebola Hemorrhagic Fever Ebola hemorrhagic fever (Ebola HF) is one of numerous Viral Hemorrhagic Fevers. It is a severe, often fatal disease in humans and nonhuman primates (such as monkeys, gorillas, and chimpanzees). Ebola HF is caused by infection with a virus of the family Filoviridae, genus Ebolavirus. When infection occurs, symptoms usually begin abruptly. The first Ebolavirus species was discovered in 1976 in what is now the Democratic Republic of the Congo near the Ebola River. Since then, outbreaks have appeared sporadically. There are five identified subspecies of Ebolavirus. -
Lesson Learned from Emerging Infectious Diseases: Are We Ready for the Next Pandemic?
Lesson Learned from Emerging Infectious Diseases: Are We Ready for the Next Pandemic? Ching Man Chan, Jenny (2nd year Mphil) Supervisor: Dr. Martin Chan Joint Graduate Seminar Department of Microbiology, Faculty of Medicine, CUHK 13th December, 2018 1 What are Emerging Infectious Diseases? Why does it matters? Emerging Infectious Diseases (EIDs) Definition Increasing frequency to describe the appearance of 1. An unrecognised infection 2. A previously recognised infection → to a new ecological niche/geographical zone → significant change in pathogenicity Facts o Infectious diseases are continuously emerging o Majority of human emerging infectious diseases are zoonoses o Those that are not zoonoses have zoonotic origins o Globalisation and human invasiveness → emergence opportunities (Howard and Fletcher, Emeging Microbes and Infections, 2012; van Doorn, Medicine (Abingdon), 2014) Severity of Emerging Infectious Diseases (Bean et al. Nature Reviews Immunology, 2013) List of Blueprint Priority Diseases 2018 o Crimean-Congo haemorrhagic fever (CCHF) o Ebola virus disease and Marburg virus disease o Lassa fever o Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS) o Nipah and henipaviral diseases o Rift Valley fever (RVF) o Zika o Disease X Why most of them are viral diseases? Where do they come from and how they evolve to infect human? Mutation Rate V.S. Genome Size (Gago et al. Science, 2009) Many of the viruses are UNKNOWN (Dr Peter Daszak’s talk on “The beginning of an end to the Pandemic Era”, Uppsala Health Summit, 2017) Emergence of Zoonoses (Wolfe, Dunavan and Diamond. Nature, 2007) Multiple Species Barrier to become Zoonotic (Bean et al. -
Perspectives in the Study of the Political Economy of COVID-19 Vaccine Regulation
Perspectives in the Study of the Political Economy of COVID-19 Vaccine Regulation Approved for publication at Regulation & Governance (DOI 10.1111/rego.12413) Elize M. da Fonseca*, Sao Paulo School of Business Administration, Getulio Vargas Foundation, Brazil, and Latin America and Caribbean Centre, London School of Economics, UK Holly Jarman, School of Public Health, University of Michigan, US Elizabeth J. King, School of Public Health, University of Michigan, US Scott L. Greer, School of Public Health, University of Michigan, US Short running title: COVID-19 Vaccine Regulation *Corresponding author Rua Itapeva 474, 7th floor Sao Paulo, SP, Brazil 01332-000 [email protected] +55 11 3799-7777 Acknowledgements: EMF is funded by the Sao Paulo Research Foundation (Fapesp) grant 2020/05230-8 and 2015/18604-5, and the FGV Applied Research Network. We declare no conflict of interest RESEARCH FORUM Perspectives in the Study of the Political Economy of COVID-19 Vaccine Regulation Vaccines against SARS-CoV-2 continue to be developed at an astonishingly quick speed and the early ones, like Pfizer and Moderna, have been shown to be more effective than many public health scientists had dared to hope. As COVID-19 vaccine research continues to progress, the world’s eyes are turning towards medicines regulators. COVID-19 vaccines need to be authorized for use in each country in which the pharmaceutical industry intends to commercialize its product. This results in a patchwork of regulations that can influence the speed at which products are launched and the standards that govern them. In this research forum article, we discuss several key questions about COVID-19 vaccine regulations that should shape research on the next stage of the pandemic response.